X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare WYETH LTD with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs SANOFI INDIA - Comparison Results

WYETH LTD    Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD SANOFI INDIA WYETH LTD/
SANOFI INDIA
 
P/E (TTM) x 27.7 39.1 70.9% View Chart
P/BV x 5.3 8.4 63.5% View Chart
Dividend Yield % 1.3 1.1 119.0%  

Financials

 WYETH LTD   SANOFI INDIA
EQUITY SHARE DATA
    WYETH LTD
Mar-13
SANOFI INDIA
Dec-16
WYETH LTD/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1,0444,560 22.9%   
Low Rs8184,400 18.6%   
Sales per share (Unadj.) Rs298.61,028.5 29.0%  
Earnings per share (Unadj.) Rs57.2129.0 44.4%  
Cash flow per share (Unadj.) Rs58.4186.0 31.4%  
Dividends per share (Unadj.) Rs17.0068.00 25.0%  
Dividend yield (eoy) %1.81.5 120.3%  
Book value per share (Unadj.) Rs249.5753.6 33.1%  
Shares outstanding (eoy) m22.7223.03 98.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.14.4 71.6%   
Avg P/E ratio x16.334.7 46.8%  
P/CF ratio (eoy) x15.924.1 66.2%  
Price / Book Value ratio x3.75.9 62.8%  
Dividend payout %29.752.7 56.3%   
Avg Mkt Cap Rs m21,157103,174 20.5%   
No. of employees `0000.53.6 13.6%   
Total wages/salary Rs m4003,592 11.1%   
Avg. sales/employee Rs Th13,787.46,537.7 210.9%   
Avg. wages/employee Rs Th813.0991.4 82.0%   
Avg. net profit/employee Rs Th2,643.3819.8 322.4%   
INCOME DATA
Net Sales Rs m6,78323,686 28.6%  
Other income Rs m353708 49.8%   
Total revenues Rs m7,13624,394 29.3%   
Gross profit Rs m1,6175,281 30.6%  
Depreciation Rs m271,313 2.0%   
Interest Rs m615 36.7%   
Profit before tax Rs m1,9384,661 41.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-50-   
Tax Rs m6321,691 37.4%   
Profit after tax Rs m1,3012,970 43.8%  
Gross profit margin %23.822.3 106.9%  
Effective tax rate %32.636.3 89.9%   
Net profit margin %19.212.5 152.9%  
BALANCE SHEET DATA
Current assets Rs m6,98415,673 44.6%   
Current liabilities Rs m2,0566,678 30.8%   
Net working cap to sales %72.638.0 191.3%  
Current ratio x3.42.3 144.7%  
Inventory Days Days9976 130.6%  
Debtors Days Days2422 107.3%  
Net fixed assets Rs m2448,098 3.0%   
Share capital Rs m227230 98.7%   
"Free" reserves Rs m5,44117,088 31.8%   
Net worth Rs m5,66817,356 32.7%   
Long term debt Rs m250-   
Total assets Rs m7,90125,400 31.1%  
Interest coverage x353.3311.7 113.3%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.9 92.1%   
Return on assets %16.511.8 140.7%  
Return on equity %22.917.1 134.1%  
Return on capital %34.026.9 126.4%  
Exports to sales %0.224.5 0.9%   
Imports to sales %36.328.0 129.9%   
Exports (fob) Rs m155,801 0.3%   
Imports (cif) Rs m2,4656,627 37.2%   
Fx inflow Rs m157,145 0.2%   
Fx outflow Rs m2,6776,846 39.1%   
Net fx Rs m-2,662299 -890.3%   
CASH FLOW
From Operations Rs m9233,226 28.6%  
From Investments Rs m317-1,555 -20.4%  
From Financial Activity Rs m-481-1,818 26.5%  
Net Cashflow Rs m759-147 -516.4%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 51.1 60.4 84.6%  
Indian inst/Mut Fund % 11.3 14.4 78.5%  
FIIs % 7.2 14.6 49.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 10.5 289.5%  
Shareholders   21,978 15,184 144.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  ELDER PHARMA  GSK PHARMA  PANACEA BIOTECH  

Compare WYETH LTD With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY18); Net Profit Up 37.5% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, SANOFI INDIA has posted a net profit of Rs 825 m (up 37.5% YoY). Sales on the other hand came in at Rs 6 bn (up 11.7% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD - GSK PHARMA COMPARISON

COMPARE WYETH LTD WITH

MARKET STATS